期刊
NATURE MEDICINE
卷 26, 期 6, 页码 869-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41591-020-0893-5
关键词
-
资金
- Rosetrees and Stoneygate Imperial College Research Fellowship
- National Institutes of Health [F31 AI22592]
- NIGMS [F32 GM115208, R01GM104371]
- Michael J. Fox Foundation for Parkinson's Research [12868]
- NIDDK [U54DK105566]
- Wellcome Trust [107469/Z/15/Z]
- Medical Research Council (UK)
- NIHR Royal Brompton Biomedical Research Unit
- NIHR Imperial Biomedical Research Centre
- Estonian Research Council [PUT1660, PRG184]
- UK Biobank Resource [42890]
- MRC [MC_UP_1102/20] Funding Source: UKRI
Analysis of large genomic datasets, including gnomAD, reveals that partial LRRK2 loss of function is not strongly associated with diseases, serving as an example of how human genetics can be leveraged for target validation in drug discovery. Human genetic variants predicted to cause loss-of-function of protein-coding genes (pLoF variants) provide natural in vivo models of human gene inactivation and can be valuable indicators of gene function and the potential toxicity of therapeutic inhibitors targeting these genes(1,2). Gain-of-kinase-function variants in LRRK2 are known to significantly increase the risk of Parkinson's disease(3,4), suggesting that inhibition of LRRK2 kinase activity is a promising therapeutic strategy. While preclinical studies in model organisms have raised some on-target toxicity concerns(5-8), the biological consequences of LRRK2 inhibition have not been well characterized in humans. Here, we systematically analyze pLoF variants in LRRK2 observed across 141,456 individuals sequenced in the Genome Aggregation Database (gnomAD)(9), 49,960 exome-sequenced individuals from the UK Biobank and over 4 million participants in the 23andMe genotyped dataset. After stringent variant curation, we identify 1,455 individuals with high-confidence pLoF variants in LRRK2. Experimental validation of three variants, combined with previous work(10), confirmed reduced protein levels in 82.5% of our cohort. We show that heterozygous pLoF variants in LRRK2 reduce LRRK2 protein levels but that these are not strongly associated with any specific phenotype or disease state. Our results demonstrate the value of large-scale genomic databases and phenotyping of human loss-of-function carriers for target validation in drug discovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据